Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs, Type, Route of Administration, and Distribution Channel

List of Tables

The Europe pulmonary arterial hypertension market is expected to grow from US$ 1,959.47 million in 2022 to US$ 2,683.07 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.

Growing Incidence of Pulmonary Arterial Hypertension Drives Europe Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) affects the tiny arteries in the lung, making it thick and narrow and blocking the blood flow through the lungs. As a result, blood pressure in the lungs increases, and the heart faces difficulties in pumping blood through narrowed arteries. Over time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women between the ages of 30 and 60. Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 7.6 cases per million in Scotland. Idiopathic PAH-in which a family history or an identified risk factor is present-is even rare, recording 2.6 cases per million in Scotland. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the Europe pulmonary arterial hypertension market.

Europe Pulmonary Arterial Hypertension Market Overview

The Europe pulmonary arterial hypertension market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the global pulmonary arterial hypertension market. The Europe pulmonary arterial hypertension market is expected to witness significant growth during the forecast period due to a rise in product approvals. Pulmonary hypertension is a rare condition that affects approximately one in 20,000 people in the UK. In 2021, 7,876 individuals in the UK suffered from pulmonary hypertension. In the UK, younger patients suffering from idiopathic pulmonary arterial hypertension (IPAH) have a 5-year survival above 80%. In the UK, patients suffering from PAH and CTEPH (the disease is caused due to a direct consequence of changes in the pulmonary vasculature) are most commonly treated in nine specialist centers across the country. The Pulmonary Hypertension Association UK (PHA-UK) in the UK advocates exclusively for people affected by pulmonary hypertension. Therefore, such initiatives are expected to fuel the pulmonary arterial hypertension drug market in the country during the forecast period.

Europe Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Europe Pulmonary Arterial Hypertension Market Segmentation

The Europe pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Europe pulmonary arterial hypertension market.

Based on route of administration, the Europe pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on country, the Europe pulmonary arterial hypertension market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and United Therapeutics Corp are the leading companies operating in the Europe pulmonary arterial hypertension market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pulmonary arterial hypertension market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00028023

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Europe Pulmonary Arterial Hypertension Market - By Drugs
- 1.3.2 Europe Pulmonary Arterial Hypertension Market - By Type
- 1.3.3 Europe Pulmonary Arterial Hypertension Market - By Route of Administration
- 1.3.4 Europe Pulmonary Arterial Hypertension Market - By Distribution Channel
- 1.3.5 Europe Pulmonary Arterial Hypertension Market - By Country

2. Europe Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Pulmonary Arterial Hypertension Market - Market Landscape

4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion

5. Europe Pulmonary Arterial Hypertension Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.2 Market Restraints
- 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
- 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.4 Future Trend
- 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - Europe Analysis

6.1 Europe Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

7.1 Overview
7.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
- 7.3.1 Overview
- 7.3.2 Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
- 7.4.1 Overview
- 7.4.2 Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
- 7.5.1 Overview
- 7.5.2 sGC Stimulators: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
- 7.6.1 Overview
- 7.6.2 Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. Europe Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

8.1 Overview
8.2 Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
- 8.3.1 Overview
- 8.3.2 Branded: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
- 8.4.1 Overview
- 8.4.2 Generics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

9.1 Overview
9.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
- 9.3.1 Overview
- 9.3.2 Oral: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
- 9.4.1 Overview
- 9.4.2 Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
- 9.5.1 Overview
- 9.5.2 Inhalational: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

10.1 Overview
10.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
- 10.3.1 Overview
- 10.3.2 Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
- 10.4.1 Overview
- 10.4.2 Online Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
- 10.5.1 Overview
- 10.5.2 Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis

11.1 Europe: Pulmonary Arterial Hypertension Market
- 11.1.1 Overview
- 11.1.2 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  - 11.1.2.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.1.1 Overview
    - 11.1.2.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.2.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.2.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.2.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.2.1 Overview
    - 11.1.2.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.2.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.2.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.2.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.2.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.3.1 Overview
    - 11.1.2.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.2.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.2.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.2.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.2.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.4.1 Overview
    - 11.1.2.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.2.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.2.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.2.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.2.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.5.1 Overview
    - 11.1.2.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.2.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.2.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.2.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.2.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.6.1 Overview
    - 11.1.2.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.2.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.2.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.2.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.2.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. Pulmonary Arterial Hypertension Market - Industry Landscape

12.1 Overview
12.2 Organic Developments
- 12.2.1 Overview
12.3 Inorganic Developments
- 12.3.1 Overview

13. Company Profiles

13.1 Johnson & Johnson
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Gilead Sciences Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 United Therapeutics Corp
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Novartis AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GSK Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Teva Pharmaceutical Industries Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Lupin Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pfizer Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms